Picton Mahoney Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Picton Mahoney Asset Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-250,000	Closed	-$10.2M	–	1009
2024 Q2	$10.2M	Buy	250,000 +100,000	+67%	+$4.16M	0.4%	91
2024 Q1	$6.34M	Sell	150,000 -75,000	-33%	-$3.15M	0.19%	132
2023 Q4	$9.54M	Buy	+225,000	New	+$6.47M	0.26%	84

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Picton Mahoney Asset Management's CERE Position: Q3 2024 in Review

Picton Mahoney Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 250,000 shares — an estimated $10.2M sold.

Picton Mahoney Asset Management first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $10.2M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Picton Mahoney Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Picton Mahoney Asset Management sold 250,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $10.2M.
Picton Mahoney Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
Picton Mahoney Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $10.2M in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Picton Mahoney Asset Management's 13F filing for Q3 2024, filed 4 Nov 2024.